NeuroOne Medical Technologies Corporation stockholders approved amendments to its 2025 Equity Incentive Plan increasing the share reserve by 1,500,000 shares and adding annual evergreen increases, elected two Class III directors, ratified the auditor, and approved a reverse stock split at the April 3, 2026 Annual Meeting.
Key takeaways
Stockholders approved First Amendment to 2025 Equity Incentive Plan, increasing share reserve by 1,500,000 new shares.
Plan now includes automatic annual increases of 5% of Fully Diluted Shares from Jan 1, 2027 to 2031, subject to Board discretion.
Jeffrey Mathiesen and Edward Andrle elected as Class III directors for three-year terms ending 2029.
Baker Tilly US, LLP ratified as independent auditor for fiscal year ending September 30, 2026.
Amendment to Certificate of Incorporation approved for reverse stock split at 1-for-2 to 1-for-15 ratio, at Board discretion.
59.72% of outstanding shares present at Annual Meeting with 30,272,834 shares voted.